Amgen Names Joshua Ofman Vice President, Reimbursement and Payment Policy Read more about Amgen Names Joshua Ofman Vice President, Reimbursement and Payment Policy
Amgen's Phase 2 Study of GDNF for Advanced Parkinson's Disease Fails to Meet Primary Endpoint; Six Months of Treatment Showed Biological Effect But No Clinical Improvement Read more about Amgen's Phase 2 Study of GDNF for Advanced Parkinson's Disease Fails to Meet Primary Endpoint; Six Months of Treatment Showed Biological Effect But No Clinical Improvement
Phase 3 Study Shows First-Cycle Administration of Neulasta Significantly Lowers Incidence of Infection and Hospitalization Read more about Phase 3 Study Shows First-Cycle Administration of Neulasta Significantly Lowers Incidence of Infection and Hospitalization
Amgen Submits Biologics License Application for FDA Approval of Palifermin Read more about Amgen Submits Biologics License Application for FDA Approval of Palifermin
New Two-Year Data Demonstrate That ENBREL Therapy Allowed Significantly More Rheumatoid Arthritis Patients to Achieve Clinical Remission Read more about New Two-Year Data Demonstrate That ENBREL Therapy Allowed Significantly More Rheumatoid Arthritis Patients to Achieve Clinical Remission
Head-to-Head Studies Show Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once a Week Read more about Head-to-Head Studies Show Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once a Week
Study Results Demonstrate Aranesp Dosed Once Every Three Weeks Achieves Treatment Goals in Managing Anemia in Cancer Patients Receiving Chemotherapy Read more about Study Results Demonstrate Aranesp Dosed Once Every Three Weeks Achieves Treatment Goals in Managing Anemia in Cancer Patients Receiving Chemotherapy
Study Results Demonstrate the Activity of Aranesp in Treating Anemia in Cancer Patients Not Receiving Chemotherapy Read more about Study Results Demonstrate the Activity of Aranesp in Treating Anemia in Cancer Patients Not Receiving Chemotherapy
Interim Phase 2 Data Show Panitumumab Has Single-Agent Antitumor Activity in Metastatic Colorectal Cancer; Response Appears Independent of Prior Chemotherapy Regimen Read more about Interim Phase 2 Data Show Panitumumab Has Single-Agent Antitumor Activity in Metastatic Colorectal Cancer; Response Appears Independent of Prior Chemotherapy Regimen
2004 Rhode Island Recipients of Amgen Award for Science Teaching Excellence Announced Read more about 2004 Rhode Island Recipients of Amgen Award for Science Teaching Excellence Announced
